Compare Stocks

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
ETON Eton Pharmaceuticals	$3.43	$3.72	$2.42 ▼ $5.81	$88.11M	1.19	66,947 shs	139,532 shs
HBPCF Helix BioPharma	$0.14	$0.14	$0.14 ▼ $0.15	$31.59M	-0.04	N/A	N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	+3.78%
ETON Eton Pharmaceuticals	-7.66%	-8.40%	-3.78%	-22.11%	-2.14%
HBPCF Helix BioPharma	0.00%	0.00%	0.00%	-5.03%	-5.75%

Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	2.39 of 5 stars	3.5	5.0	0.0	0.0	2.3	0.8	0.0
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	3.00	Buy	$9.00	162.39% Upside
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest HBPCF, ADMS, ETON, and APTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/6/2024	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
ETON Eton Pharmaceuticals	$31.64M	2.78	N/A	N/A	$0.60 per share	5.72
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	8/8/2024 (Estimated)
HBPCF Helix BioPharma	-$4.69M	-$0.04	N/A	∞	N/A	N/A	-817.64%	-308.71%	6/12/2024 (Estimated)

Latest HBPCF, ADMS, ETON, and APTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2024	Q1 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.03	-$0.01	-$0.03	$8.30 million	$7.97 million
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
APTX Aptinyx	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	1.65	1.60
HBPCF Helix BioPharma	N/A	1.46	1.46

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
APTX Aptinyx	N/A
ETON Eton Pharmaceuticals	27.86%
HBPCF Helix BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
APTX Aptinyx	10.97%
ETON Eton Pharmaceuticals	13.16%
HBPCF Helix BioPharma	7.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
HBPCF Helix BioPharma	9	229.44 million	212.00 million	Not Optionable

HBPCF, ADMS, ETON, and APTX Headlines

Source	Headline
	Helix Dusk Luxe Mattress Review 2024: A Comfortable Pillow-Top Bed cnet.com - April 17 at 5:42 PM
	Helix BioPharma Corp. Reports Voting Results finance.yahoo.com - January 22 at 12:58 PM
	Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results finance.yahoo.com - December 14 at 7:26 PM
	Helix BioPharma Corp HBP morningstar.com - November 28 at 11:29 PM
	Helix Biopharma GAAP EPS of -C$0.03 msn.com - October 27 at 9:54 PM
	Helix BioPharma Corp. Announces Fiscal 2023 Year-End Results finance.yahoo.com - October 27 at 9:54 PM
	Helix BioPharma Corp. (HBP) uk.investing.com - September 14 at 6:01 PM
	HELIX BIOPHARMA CORP (HBPCF) stock forecast and price target finance.yahoo.com - June 29 at 2:20 PM
	15 Best Memorial Day Mattress Sales You Can Shop Right Now: Nectar, Helix, Tempur-Pedic and More etonline.com - May 24 at 6:58 PM
	Helix Energy Up on BP Spill Contract thestreet.com - May 14 at 7:33 PM
	Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results finance.yahoo.com - March 15 at 6:50 PM
	Reflections on the Double Helix’s Platinum Anniversary genengnews.com - February 2 at 8:59 AM
	Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - January 31 at 7:31 AM
	Helix BioPharma appoints R&D head seekingalpha.com - September 3 at 9:46 PM
	Proactive news headlines including Shell, Maverix Metals, Helix BioPharma, Wellteq Digital Health and Trees Corp benzinga.com - September 2 at 3:43 PM
	Helix Biopharma Corp. Announces Appointment of New Chief Financial Officer finance.yahoo.com - May 18 at 9:52 AM
	Helix BioPharma appoints Artur Gabor as its new CEO; adds three new board members ca.proactiveinvestors.com - April 18 at 2:01 PM
	Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription finance.yahoo.com - April 13 at 6:17 PM
	Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription finance.yahoo.com - April 13 at 6:17 PM
	Helix Biopharma GAAP EPS of -$0.01 seekingalpha.com - March 18 at 7:10 AM
	Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board finance.yahoo.com - March 16 at 10:32 AM
	Helix Biopharma Corp. (HBPCF) nasdaq.com - January 28 at 11:33 PM
	Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director finance.yahoo.com - January 28 at 6:33 PM
	Helix Biopharma: Fiscal Q1 Earnings Snapshot timesunion.com - December 15 at 8:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Helix BioPharma

OTCMKTS:HBPCF

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial